Alexion’s Soliris (eculizumab) Receives FDA’s Approval for Anti-Aquaporin-4 Antibody Positive Patients with Neuromyelitis Optica Spectrum Disorder

 Alexion’s Soliris (eculizumab) Receives FDA’s Approval for Anti-Aquaporin-4 Antibody Positive Patients with Neuromyelitis Optica Spectrum Disorder

Alexion’s Soliris (eculizumab) Receives FDA’s Approval for Anti-Aquaporin-4 Antibody Positive Patients with Neuromyelitis Optica Spectrum Disorder

Shots:

  • The approval is based on P-III PREVENT study results assessing Soliris vs PBO in patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive
  • The P-III PREVENT study results: @48wks. & @144wks. relapse free patients (98% & 96% vs 63% & 45%); relapse free patients without receiving IST @144wks. (100% vs 20%)
  • Soliris is a complement inhibitor, inhibiting the C5 protein in a complement cascade, approved in the US, EU & Japan for PNH & aHUS and is under EMA & MHLW’s review for NMOSD

Click here to read full press release/ article | Ref: Alexion | Image: The Valley Breeze

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post